
Lupin's CNS Anchor—When Pitolisant Approval Meets Competitive Generic Density
USFDA approval · Pitolisant · CNS drugs

USFDA approval · Pitolisant · CNS drugs

CDMO · Trade Generics · Plant 6

14 consecutive quarters · CDMO 29% growth · TGx stagnant

margin collapse · acquisition dependency · organic stagnation

acquisition-led growth · margin pressure · raw material inflation

earnings beat · organic growth · material costs

Revenue +21% · Guide raised · Biotech 7-pipeline

earnings review · revenue guidance · Aequitas acquisition

brand_led_growth · semi_chronic_shift · aequitas_acquisition

earnings review · sequential weakness · Raipur profitability

specialty mix ARPOB · Raipur unprofitable · sequential decline

earnings · transformation · CDMO

CDMO · Formulation launches · Biologics scaling

CDMO · Jammu facility · volume growth

volume growth · CDMO demand · Jammu ramp

FDA remediation · leverage drag · Pharma CDMO

FDA remediation · Animal Health scaling · CDMO partnerships

pricing power · volume miss · capacity ramp

pricing power · capacity ramp-up · volume miss

HCG · oncology · ARPP stagnation

payor mix · EBITDA margin expansion · volume growth

diagnostics · capex expansion · tier-2

network expansion · margin resilience · B2C leverage

revenue growth · margin recovery · battery materials

PFN 31% growth · battery materials · greenfield Q3

CDMO · ADC · oligonucleotides

NJ Bio drag · Phase 3 conversions · Sapala growth

margin compression · new unit ramp · PAT cliff

new unit ramp · margin pressure · debt reduction

merger-integration · synergies-pending · margin-compression